Long-Term Immunomodulatory Impact of VNS on Peripheral Cytokine Profiles and Its Relationship with Clinical Response in Difficult-to-Treat Depression (DTD)

Erhan Kavakbasi,Evelien Van Assche,Kathrin Schwarte,Christa Hohoff,Bernhard T. Baune
DOI: https://doi.org/10.3390/ijms25084196
IF: 5.6
2024-04-10
International Journal of Molecular Sciences
Abstract:Vagus nerve stimulation (VNS) represents a long-term adjunctive treatment option in patients with difficult-to-treat depression (DTD). Anti-inflammatory effects have been discussed as a key mechanism of action of VNS. However, long-term investigations in real-world patients are sparse. In this naturalistic observational study, we collected data on cytokines in peripheral blood in n = 6 patients (mean age 47.8) with DTD and VNS treatment at baseline and at 6 months follow-up. We have identified clusters of peripheral cytokines with a similar dynamic over the course of these 6 months using hierarchical clustering. We have investigated cytokine changes from baseline to 6 months as well as the relationship between the cytokine profile at 6 months and long-term response at 12 months. After 6 months of VNS, we observed significant correlations between cytokines (p < 0.05) within the identified three cytokine-pairs which were not present at baseline: interleukin (IL)-6 and IL-8; IL-1β and TNF-α; IFN-α2 and IL-33. At 6 months, the levels of all the cytokines of interest had decreased (increased in non-responders) and were lower (5-534 fold) in responders to VNS than in non-responders: however, these results were not statistically significant. VNS-associated immunomodulation might play a role in long-term clinical response to VNS.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The paper attempts to address the issue of the immunomodulatory effects of long-term vagus nerve stimulation (VNS) treatment on the peripheral blood cytokine profile in patients with treatment-resistant depression (TRD) and its relationship with clinical response. Specifically, the study aims to: 1. **Explore changes in the cytokine profile after VNS treatment**: By analyzing the peripheral blood cytokine levels at baseline and at 6-month follow-up in 6 patients with treatment-resistant depression, identify the dynamic changes in cytokines during the VNS treatment process. 2. **Identify cytokine clusters and their correlations**: Using hierarchical clustering methods, identify cytokine clusters that emerge at the 6-month follow-up and investigate the changes in correlations of these cytokines within the clusters from baseline to 6 months. 3. **Evaluate the relationship between cytokine changes and clinical response**: Study the relationship between cytokine levels at 6 months and clinical response status at 12 months, aiming to find biomarkers for early prediction of VNS treatment efficacy. ### Main Findings: - **Formation of cytokine clusters**: After 6 months of VNS treatment, three significant cytokine pairs were observed: IL-6 and IL-8, IL-1β and TNF-α, IFN-α2 and IL-33. These cytokine pairs showed no correlation at baseline but exhibited high correlation at 6 months. - **Changes in cytokine levels**: Responders generally showed a decrease in cytokine levels at 6 months, while non-responders showed an increase. Although these changes were not statistically significant, this may be related to the small sample size. - **Relationship between early cytokine changes and long-term clinical response**: Cytokine levels at 6 months may help distinguish future responders from non-responders, suggesting that VNS may exert its effects through immunomodulatory mechanisms early on, while clinical responses take longer to manifest. ### Significance: - **Immunomodulatory mechanisms**: The findings support the idea that VNS exerts its antidepressant effects through immunomodulatory mechanisms, particularly by regulating the cytokine network. - **Early predictive indicators**: Changes in the cytokine profile at 6 months may serve as potential biomarkers for early prediction of VNS treatment efficacy, aiding clinical decision-making. ### Limitations: - **Small sample size**: The study includes only 6 patients, which may lead to insufficient statistical power of the results. - **Uncontrolled design**: The study is a natural observational study without a control group, which may affect the interpretation of the results. Overall, this study provides new insights into the immunomodulatory effects of VNS in treatment-resistant depression and lays the foundation for further research.